Tumor necrosis factor (TNF) and lymphotoxin alpha (LTA) influence a variety of cellular responses and play a complex role in the immune response. Several single nucleotide polymorphisms (SNPs) have been reported in these major histocompatibility complex (MHC)-linked loci; however, a comprehensive examination of polymorphisms in the promoter regions of TNF and LTA has not been carried out and was undertaken here. Seven novel SNPs in LTA were identified by sequence analysis of 69 samples. Eight novel TNF alleles and 16 novel LTA alleles were designated. The TNF alleles clustered into two closely related groups, while the LTA alleles clustered into three distinct groups using phylogenetic and percentage difference analyses. A total of 52 unique TNF-LTA-HLA haplotypes are reported. There appear to be some associations between TNF/LTA alleles and HLA haplotypes, but not with specific HLA alleles. The majority of the SNPs appear to be randomly associated within and between the two loci except for the LTA SNPs at À293, þ 81 and þ 369. These observations may provide an explanation for the oftentimes contradictory results of studies associating individual cytokine gene SNPs with expression level phenotypes, HLA and disease.
Introduction
Tumor necrosis factor (TNF [a] ; cachectin) and lymphotoxin alpha (LTA; TNFb) are structurally homologous inflammatory cytokines produced primarily, but not exclusively, by macrophages and T cells, respectively. 1, 2 Initially identified for their cytotoxic and antitumor activity, 3, 4 it is now well documented that these cytokines play critical roles in a variety of immunologic processes including inflammation, secondary lymphoid organ development and the control of intracellular pathogens. 1, [5] [6] [7] TNF and LTA are expressed in various different forms 2 and bind to multiple receptors to perform their functions. 2, 8, 9 The TNF and LT loci are tandemly arranged in the class III region of the human major histocompatibility complex (MHC) (Figure 1a ) approximately 220 kb centromeric to the HLA-B locus. 10, 11 These genes, each of which consists of four exons, are tightly linked. Only 1240 bases separate the polyadenylation site of LTA and the transcription start site of TNF. Like most cytokine genes, TNF and LTA gene expression is highly regulated. [12] [13] [14] Several single nucleotide polymorphisms (SNPs) have been reported in these loci, although lack of a consistent numbering system has hampered comparison of studies. Multiple SNPs are found in the TNF locus [15] [16] [17] [18] [19] ( Figure  1b ), including 10 located in the promoter upstream of the transcription start site at À1073 (C/T), À1031 (T/C), À863 (C/A), À857 (C/T), À575 (G/A), À376 (G/A), À308 (G/A), À244 (G/A), À238 (G/A) and À163 (G/A). Two SNPs are located in exon 1 within the 5 0 untranslated region (UTR) at þ 70 (C insertion) 20 and þ 153 (C/T). 21 Several SNPs also have been reported in the introns 18 and a G/T dimorphism is present in the 3 0 UTR. 10, 22 Nine SNPs have been reported in the LTA locus [23] [24] [25] [26] [27] [28] ( Figure 1c ). Three are located in the promoter region upstream of the transcription start site at À626 (G/A), À294 (C/T) and À293 (G/A). In exon 1, which encodes the majority of the 5'UTR, there are two SNPs at þ 11 (G/A) and þ 81 (C/A). Two SNPs are found in the first intron, one at þ 253 (G/A) that is detectable by an NcoI restriction fragment length polymorphism (RFLP) and the other at þ 369 (G/C) that is detectable by an AspHI RFLP. There is an SNP located at þ 496 (T/C) in exon 2 that causes a cysteine to arginine change, respectively, at amino-acid position À21 in the signal sequence. Lastly, an SNP is located at þ 724 (C/A) in exon 3, which creates a threonine to asparagine change, respectively, at amino-acid position 26 of the mature protein.
In addition, a (CT)n dinucleotide repeat (n¼9-10) is located in intron 1 and defines the TNFc microsatellite.
A limited number of studies have directly examined the effects of some of these polymorphisms on expression and transcription factor binding. 27, 28, [30] [31] [32] [33] [34] [35] On the other hand, there have been numerous studies, which have correlated specific SNPs to TNF and to LTA expression levels in groups of individuals and from cell lines, but with varying results. [36] [37] [38] [39] [40] It is understood that the production level phenotype of an individual cytokine can have a major impact on immune responsiveness, and an abundance of studies have linked specific SNPs to disease. 41, 42 As examples, TNF and LTA expression levels and SNPs have been shown to correlate with an individual's susceptibility to, severity of and/or prognosis of diseases such as HIV, multiple sclerosis and cerebral malaria [43] [44] [45] [46] and with prognosis or outcome of allograft transplantation and malignancies. 7, [47] [48] [49] Because of their linkage to HLA genes in the MHC and their biologic properties, it is speculated that TNF and/or LTA also may contribute to the etiology of MHC-associated autoimmune diseases such as systemic lupus erythematosus, 50, 51 insulin-dependent diabetes mellitus, 52, 53 myasthenia gravis 54, 55 and rheumatoid arthritis. 56, 57 Furthermore, TNF and LTA expression level phenotypes and individual SNP also have been associated with particular HLA types. [58] [59] [60] [61] Although there are a plethora of studies suggesting an association between TNF and LTA SNPs, expression level phenotypes, HLA and disease, there are as many studies that are in conflict or that find no correlation. 36, 41, 42, 50, 62, 63 As these types of studies examine either individual SNP or a subset of the reported SNPs, the discrepent results are likely to be a result of the linked SNPs that were not examined. To our knowledge, no study to date has taken into account all of the SNPs at these loci when assessing the effects on expression or the linkage to disease and HLA. For these reasons, the extent of polymorphism in the TNF and LTA promoter regions was investigated. Promoter 'alleles' at each locus were determined and the relatedness of the alleles was examined by phylogenetic analysis. Finally, TNF and LTA alleles were included in HLA haplotypes and associations were examined.
Results
Several novel SNPs in the LTA locus TNF and LTA were characterized by sequencing from 69 samples to determine the extent of polymorphism at these loci. The samples were chosen to include individuals from a variety of racial backgrounds and with a variety of HLA haplotypes. The TNF fragment (1236 bp) that was analyzed encompasses the region from þ 161 just upstream of the translation start site in exon 1 to À1075 in the promoter (Figure 1b) . Primer sites were chosen for specificity, to include the largest promoter region fragment between the translation start site of the TNF gene and the 3 0 end of the LTA gene and to ensure coverage of all 12 of the previously reported promoter region SNPs. The transcription start site ( þ 1) of TNF has not been mapped and studies have been inconsistent as to its exact location. Therefore, we have positioned the transcription start site as to locate one of the most studied SNPs at À308. Base numbering and the position of the remaining SNPs coincide with our sequence data. No novel polymorphisms were identified in the TNF promoter region fragment from any of the samples that were examined; however, seven of the 12 previously reported TNF SNPs were present.
The 3177 bp LTA fragment (À2434 to þ 743) included all previously reported SNPs, the TNFc microsatellite and an extended promoter region (Figure 1c ). The choice to examine an extended promoter region was based on a study of the interleukin-10 promoter, which showed SNPs associations with production level phenotypes in an additional 3.0 kb fragment upstream of the 1.0 kb proximal promoter region fragment that was originally analyzed. 64 Designation of the transcription start site ( þ 1) was based on its mapping by S1 nuclease, 22 although the authors noted that there may be some heterogeneity in its location. Base numbering and position of SNPs coincide with our sequence data. Seven novel or unreported SNPs were identified, as well as a 145 bp insertion. Five of these SNPs were found in the region upstream of the transcription start site: À2066 (C/T), À1816 (C/G), À1783 (G/A), À1563 (A/T) and À1051 (G/A). A novel SNP was identified at þ 633 (G/ C), which falls in the second intron. Finally, a novel SNP at position þ 697 (A/C) changes histidine to proline, respectively, in the mature protein at amino acid 17.
Two of the seven novel SNPs at positions À1816 and À1563 also are seen on alignment and comparison of all GenBank LTA sequences which overlap the fragment examined in this study (data not shown). Further, a 145 bp insertion was found in one sample (9075) at position À425. This insertion is actually a duplication of the promoter sequence between positions À570 and À426 and was present in one GenBank LTA sequence (accession #AF037255).
Promoter 'alleles' of TNF and LTA Alleles of the TNF promoter and LTA promoter were determined by family segregation analysis and by sequencing of cloned DNA or MHC homozygous cell lines. Allele names were designated p* to denote that they were based on the sequence of the promoter region which was defined as the nucleotide positions upstream of the translation start site ( þ 181 for TNF and þ 460 for LTA). This is followed by a three-digit number to denote a unique allele. For example, TNFp*001 denotes promoter allele 1 of TNF. An additional two digits were added to allele names (TNFp*00101 and TNFp*00102, for example) to denote that the alleles have identical promoter regions, but differ downstream of the translation start site. GenBank sequences that fully overlapped the TNF and LTA fragments were included in the 'allele' assignment.
Eight novel TNF alleles were present in the samples examined (Table 1) . Allele TNFp*001 was designated as such because it was by far the most predominant (43 haplotypes) and was identical to three GenBank sequences (accession #AF129756, AL662801 and Y14768). The remaining alleles were named in the order that they were identified. Allele TNFp*002 (eight haplotypes) differs from TNFp*001 at À308 (A vs G, respectively) and was a match (100%) to one GenBank sequence (accession #AL662847). TNFp*002 is the only allele to encode À308A, which has been associated with a high TNF expression level phenotype. All GenBank sequences that fully overlapped the TNF fragment matched alleles reported in this study. TNFp*003 (five haplotypes), TNFp*004 (two haplotypes) and TNFp*007 (four haplotypes) each also differ by only one SNP from TNFp*001, a cytosine to thymine change at À857 (TNFp*003), a thymine to cytosine change at À1031 (TNFp*004) and a guanine to adenine change at À244 (TNFp*007). TNFp*006 (9 haplotypes) and TNFp*008 (1 haplotype) each differ by two SNPs from TNFp*001. TNFp*006 encodes adenine instead of cytosine (TNFp*001) at À863 and TNFp*008 encodes adenine instead of guanine (TNFp*001) at À238, while both encode cytosine at position À1031 (TNFp*001 encodes thymine). The most distinct allele is TNFp*005 (three haplotypes), which differs from TNFp*001 by three SNPs: À1031 (T-C), À376 (G-A) and À238 (G-A) (TNFp*001-TNFp*005).
A total of 16 novel LTA alleles were identified ( Table 2 ) with 15 of these encoding unique promoter regions. Allele LTAp*001 was designated as such because it matched (100%) two GenBank sequences (accession #AP000505 and Y14768), one of which was the first LTA sequence reported. Allele LTAp*00201 was named as such because it also was identical (100% match) to one GenBank sequence (accession #AF129756). All GenBank sequences that fully overlapped the LTA fragment match alleles reported in this study. The remaining alleles were named in the order that they were identified. When compared to allele LTAp*001, the remaining 15 alleles differed by as few as a single SNP (LTAp*009 and LTAp*010) to as many as nine SNPs (LTAp*008). Three alleles predominated in the samples examined, 
Position relative to transcription start site (+1). All positions reported to be polymorphic are included, although the alternate nucleotide may not have been present in the samples examined. b Promoter defined as nucleotide positions upstream of the translation start site (+181, ATG codon) which includes the 5' untranslated region (UTR) encoded in exon 1. TNF promoter allele sequences can be accessed from GenBank: TNFp*001 (accession #AY274889 and AY274896), TNFp*002 (accession #AY274893 and AY274901), TNFp*003 (accession #AY274890 and AY274895), TNFp*004 (accession #AY274898), TNFp*005 (accession #AY274891 and AY274900), TNFp*006 (accession #AY274894 and AY274899), TNFp*007 (accession #AY274892 and AY274902) and TNFp*008 (accession #AY274897). c GenBank sequence accession #Z15026, which encompassed both TNF and LTA, was excluded. This sequence was derived from IHWS reference cell 9031 (BOLETH), which was examined in this study. The Z15026 sequence contained numerous nucleotide differences that were not seen in the TNF and LTA sequences obtained in this study from 9031 or any other sample, as well as in any of the other GenBank sequences. d This allele was a match (100%) to three GenBank sequences (accession #AF129756, AL662801 and Y14768) over the region examined. e This allele was a match (100%) to one GenBank sequence (accession #AL662847) over the region examined.
LTAp*001 (16 haplotypes) LTAp*00201 (19 haplotypes) and LTAp*004 (13 haplotypes). Seven of the alleles were found in only one haplotype (LTAp*006, LTAp*008, LTAp*010, LTAp*011, LTAp*012, LTAp*014 and LTAp*015). The remainder of the alleles were present in low to moderate numbers: LTAp*00202 (two haplotypes), LTAp*003 (four haplotypes), LTAp*005 (six haplotypes), LTAp*007 (eight haplotypes), LTAp*009 (two haplotypes) and LTAp*013 (two haplotypes). The length of the TNFc microsatellite did not factor into the allele designations, as each was unique with regard to SNP content.
Relatedness of TNF alleles and of LTA alleles
The relatedness of the TNF alleles and of the LTA alleles was determined by the construction of phylogenetic trees using the neighbor-joining method with Kimura twoparameter correction. All of the TNF allelic sequences form a relatively tight cluster ( Figure 2 ). This was expected due to the high degree of homology (X98% ;  Table 3 ) among the TNF promoter sequences. However, two groups of TNF sequences can be identified that appear to be based on the SNP at position À1031. TNF group À1031C includes TNFp*004, TNFp*005, TNFp*006 and TNFp*008. TNF group À1031T includes the remaining alleles.
The LTA allelic sequences clustered into three groups in the evolutionary tree based on the TNFc microsatellite and shared blocks of SNPs (Figure 3) . The LTA sequences with the TNFc (n¼9) microsatellite clustered into two distinct groups. TNFc (n¼9) group 1 consisted of alleles LTAp*001, LTAp*009 and LTAp*010. TNFc (n¼9) group 2 included the remaining TNFc (n¼9) sequences such as alleles LTAp*00201, LTAp*007 and LTAp*013. The split appears to be based on a shared block of SNPs from À293 to þ 369 (see Table 2 ). Group 1 members encode the block A-G-A-A-C, while group 2 sequences encode the block G-A-C-G-G. Members of group 1 also share an upstream block of SNPs from þ 496 to þ 724 (T-G-A-C), which is variable in group 2.
The third group of LTA sequences was composed of all alleles with the TNFc (n¼10) microsatellite. These alleles share a block of SNPs from À293 to þ 496 (G-G-C-A-G-C). This block of SNPs is equidistant from the same block of SNPs in each group of TNFc (n¼9) sequences (see Table 2 ); TNFc (n¼9) group 1 shares þ 11G, þ 253A and þ 496C, while TNFc (n¼9) group 2 shares À293G, þ 81C and þ 369G. Calculation of percentage difference using an allele from each group of LTA alleles as a reference sequence (Table 4) showed that each cluster of LTA alleles is equidistant from the others. Members of each 
Position relative to transcription start site (+1).
b
Promoter defined as nucleotide positions upstream of the translation start site (+460). This includes exon 1, intron 1 and the first nine bases of exon 2. LTA promoter allele sequences can be accessed from GenBank: LTAp*001 (accession #AY274908 and AY274915), LTAp*00201 (accession #AY274910 and AY274918), LTAp*00202 (accession #AY274903 and AY274925), LTAp*003 (accession #AY274909 and AY274916), LTAp*004 (accession #AY274913 and AY274920), LTAp*005 (accession #AY274905 and AY274914), LTAp*006 (accession #AY274904), LTAp*007 (accession #AY274911 and AY274912), LTAp*008 (accession #AY274926), LTAp*009 (accession #AY274906 and AY274923), LTAp*010 (accession #AY274922), LTAp*011 (accession #AY274907), LTAp*012 (accession #AY274917), LTAp*013 (accession #AY274919), LTAp*014 (accession #AY274921) and LTAp*015 (accession #AY274924). TNF and LTA, novel SNPs, alleles and haplotypes PE Posch et al LTA sequence group were 490% homologous (o0.10% different) to each other when compared to the reference sequence from that group. When the designated LTA reference sequence from each group was compared to each of the LTA sequences in the other two groups, the homology ranged from B72 to 88% (0.12-0.28% different) for each group of LTA alleles. There also appears to be two distinct subgroups of TNFc (n¼10) LTA sequences based solely on the SNP at À294. TNFc (n¼10) group 1 (LTAp*003, LTAp*005, LTAp*011 and LTAp*014) encodes À294C, while TNFc (n¼10) group 2 (LTAp*004 and LTAp*012) encodes À294T.
Inclusion of TNF and LTA alleles in HLA haplotyes Haplotypes including TNF, LTA and HLA-A, -C, -B and -DRB1 were evaluated because the TNF and LT loci are located in the MHC, have been associated via SNPs to particular HLA alleles and have been implicated in Figure 2 Relatedness of the TNF promoter alleles. The tree was constructed using the neighbor-joining method with Kimura twoparameter correction as described in Materials and methods. Figure 3 Relatedness of the LTA promoter alleles. The tree was constructed using the neighbor-joining method with Kimura two-parameter correction as described in Materials and methods. Although the sample size was small, there does appear to be a relatively tight association between specific TNF and LTA alleles. For example, TNFp*002 was always found associated with LTAp*007 (four haplotypes) and LTAp*00201 was always found associated with either TNFp*001 or TNFp*007 (15 haplotypes). In fact, each LTA allele was strongly associated with either one or two TNF alleles in all of the haplotypes identified. This would be expected because of the very short distance (1240 bp) between the TNF and LTA genes. There was only one exception noted to the association between TNF and LTA alleles. From the perspective of the TNF locus, TNFp*001 was found associated with at least 10 of the 16 LTA alleles. This observation is not surprising since TNFp*001 was by far the most predominant TNF allele and was present in over 50% of the haplotypes that were examined.
Discussion
The goals of this project were to explore the extent of polymorphism in the promoter regions of the TNF and LTA genes, to designate 'alleles' at each locus and to examine associations among SNPs, alleles and HLA. The TNF and LTA loci were characterized in 69 samples from various racial backgrounds with a variety of HLA haplotypes. Polymorphism in the TNF promoter was limited within the sample group. Of the 12 previously reported SNPs, only seven were present and no novel SNPs were identified. However, eight highly related novel TNF promoter alleles were designated. LTA proved to be highly polymorphic. Seven novel SNPs and an insertion were identified in addition to the nine SNPs that were previously reported. The abundance of SNPs led to the designation of 16 novel LTA alleles which clustered into three distinct phylogenetic groups. Finally, this sample group yielded 52 unique TNF-LTA-HLA haplotypes.
Multiple alleles of TNF and LTA were reported here. Others also have predicted 'alleles' or 'haplotypes' of TNF based on associations of a subset of SNPs. 34, 59, 62, 65 In each case, some of the reported 'allelic' SNP associations were contained in multiple TNF alleles identified here (Table 6 ). For instance, 'allele' TNFA-U01 identified by Matsushita et al 59 is included in TNFp*001, TNFp*002 and TNFp*007, while 'allele' TNFA-U04 identified by Tsuchiya et al 65 is included in TNFp*005 and TNFp*008. There were three alleles in one report that were not seen in this study. This was not surprising as it is expected that additional alleles will be identified. These observations support the importance of comprehensive nucleotide sequence characterization at the TNF and LTA loci.
There have been numerous reports of associations among individual SNPs within and between the TNF and LTA loci and their relationship to expression levels, HLA and disease. 18, 23, 40, 58, 63, 66 When associations of individual SNPs among the TNF and LTA alleles were examined in this study, only a single association was observed. In each of the alleles described, the LTA SNP À293A was always found in association with LTA þ 81A and LTA þ 369C, while the LTA SNP À293G was always found associated with LTA þ 81C and LTA þ 369G. Another tight, but not absolute, LTA SNP association (15 of the 16 alleles) was noted between the SNP at þ 253 (NcoI RFLP) and þ 724 ( þ 253A with þ 724C and þ 253G with þ 724A). The remainder of the SNPs within and between the TNF and LTA loci appear to be randomly associated. Other associations could be noted, but are dependent on the context. For example, an association could be assigned between the SNPs TNF À308A, LTA þ 253G (NcoI RFLP; TNFB*1) and LTA þ 724A, which has been observed by others. 23, 25, 27, 28, 40 Interestingly, each of these SNPs generally have been associated with higher production level phenotypes of both TNF and LTA, with the 8.1 ancestral HLA haplotype AA  3002  0804  8101  1201  001  00201  9077  API  0207  0102  4601  120201  001  00201  2011  AA  1101  0704  1801  1301  001  00201  2011  AA  020101  040101  3502  1302  001  00201  9053  API  3303  1403  440301  1302  001  00201  2006  AA  2301  040101  5301  1401  001  00201   1261  AA  030101  020204  3901  1001  001  00202  S21   d   IC  ND  ND  5301  ND  ND  00202   9020  C  2601  0501  1801  0301  005  003  9085  C  3002  0501  1801  030101  005  003  9052  C  0201  0602  5701  0701  008  003   9031  C  0201  0304  1501  0401  006  004  9032  C  0201  0304  1501  0401  006  004  2015  AA  020101  1601  4501  110102  006  004  1179  AA  020101  1601  4501  1102  006  004  1193  AA  3303  1601  4501  110102  006  004  9058  AA  0201  1601  4501  1301  004  004  9097  C  0201  0304  4001  1302  006  004  9097  C  0301  0304  4001  1302  006  004  9064  AI  0217  0303  1501  1402  006  004  DT23   c   Cam  2301 3004  040101 0802  1403 3501  1114 1322  001  00201 004   1083  AA  3001  0701  5801  090102  001  005  2015  AA  3303  030402  2703  1102  001  005  9042  C  2402  0401  3508  1103  001  005  1100  AA  2301  0701  1503  130201  001  005  1183  AA  3201  0802  1405  130301  001  005  1100  AA  2902  020204  5801  1503  001  005   2006  AA  680101  0602  5802  1103  001  006   9022  C  0101  0701  0801  0301  002  007  9023  C  0101  0701  0801  0301  002  007  9086  C  0101  0701  0801  0301  002  007  1060  LI  2402  0701  0801  030101  002  007  1083  AA  0102  0701  4901  130201  002  007  DT29  Cam  7401  020204  1503  1503  002 Haplotypes could not be resolved due to heterozygosity at two or more loci. These cell lines were included because they carried a less frequent or unique TNF or LTA allele or because they carried a unique combination of TNF and LTA alleles. These cell lines were not included in the count of unique haplotypes, but were included in the count of haplotypes carrying specific TNF and LTA alleles. In most cases, there was insufficient sample to complete typings (ND¼not determined). These cell lines were included because they carried a less frequent or unique TNF or LTA allele. These cell lines were not included in the count of unique haplotypes, but were included in the count of haplotypes carrying specific TNF and LTA alleles. 
TNF promoter 'alleles' identified in this study that contain the 'allelic' sequence previously reported. b ND¼not determined. c These SNP combinations were not seen in the alleles identified in this study.
and with MHC-linked autoimmune diseases. 24, 37, 67 This apparent association of SNPs results from the linkage of the TNFp*002 (À308A) allele with the LTAp*007 ( þ 253G, þ 724A) allele in several haplotypes, including the 8.1 ancestral haplotype (A1, B8, DR3). However, this association only holds from the perspective of the TNF À308A SNP, as it is not possible to type for either of the LTA SNPs and assume linkage. Both LTA þ 253G and LTA þ 724A were found associated more frequently with TNF À308G (found in TNFp*001 and TNFp*007). The LTA þ 253G SNP also can be associated with LTA þ 724C (found in LTAp*013). One study also placed LTA þ 11A (also found in LTAp*007) within the TNF À308A, LTA þ 253G and LTA þ 724A SNP association, 27 but this SNP also can be associated with TNF À308G and LTA þ 724C. Therefore, the context in which SNP associations are reported is of consequence.
It is well documented that differences exist in cytokine expression levels between individuals and that these differences are due to some of the SNPs carried by the individual at that locus. Consequently, a multitude of studies have linked cytokine expression level phenotypes with either individual SNPs or combinations of SNPs, oftentimes with the reporting of contradictory results. 41, 42 The LTA SNP at þ 253 (NcoI RFLP; TNFB) is a classic example of these types of studies as this SNP has been associated with both TNF and LTA expression levels. In the case of TNF, there have been several conflicting studies correlating TNF expression levels with the LTA NcoI RFLP. 23, 37, 38, 60, 68 Some light may be shed by using examples from a study by Abraham et al, 37 who measured TNF levels from cell lines (also examined in this study) carrying various ancestral haplotypes and typed for the LTA NcoI RFLP. Although a range of TNF levels were noted, higher mean TNF levels were reported with LTA þ 253G (NcoI RFLP; TNFB*1) particularly in the 8.1 ancestral haplotype, but there were intermediate and low TNF producing cell lines that also possessed the þ 253G SNP. In our study, LTA þ 253G (TNFB*1) was contained in seven distinct alleles which were linked to three distinct TNF alleles and LTA þ 253A (TNFB*2) was contained in nine unique alleles which were linked to five different TNF alleles. The TNF expression level results obtained by Abraham Studies correlating LTA expression levels with the LTA NcoI RFLP have produced similarly contradictory results. 41, 42 For example, the TNFB1 allele (LTA þ 253G, NcoI RFLP) has been correlated with both increased 23 and decreased 39 LTA expression levels, while a third study found no correlation between this SNP and LTA expression levels. 60 Each of these studies were very similar in design with the exception of the HLA types of the individuals examined. The variety of HLA types of the subjects in the first two studies was limited and also differed. It is possible that the subjects in these two studies carried different subsets of LTA alleles and that, by chance, the LTA alleles, which were represented, skewed the expression level results. However, the latter study, which found no correlation between the LTA SNP at þ 253 and LTA expression levels, measured LTA levels from subjects with a wider variety of HLA types likely representing a broader set of LTA alleles. Collectively, these observations again suggest that allelic, not SNP, typing at the TNF and LTA loci would be more informative for these types of studies. Interestingly, when the LTA þ 253 SNP was examined with more direct methods for its effect on LTA expression, 27, 28 conflicting results also were obtained.
Multiple studies have associated specific SNPs in either the TNF or LTA locus with HLA-B and/or HLA-DR as these loci flank the MHC class III region which contains the TNF and LTA genes. 58, 66, 68, 69 Although a definitive answer to linkage will likely require more comprehensive population studies, this study found no association of individual HLA-B or HLA-DRB1 alleles with specific SNPs in either TNF or LTA. For example, both DR2 (DRB1*1501) and DR3 (DRB1*0301) were linked with various TNF promoter alleles that encode À308G and that encode À308A. 60, 68 On the other hand, there were three instances in which different cell lines that carried the same HLA haplotypes also carried the same TNF and LTA alleles. These results lend support to previous reports of associations between HLA haplotypes and specific TNF and LTA SNPs. 24, 25, 67, 70 However, there was an instance in which cell lines carrying identical HLA haplotypes were found associated with different combinations of TNF and LTA alleles. The difference between these cell lines was in the LTA allele that was present in the haplotype, LTAp*00201 (1060) and LTAp*013 (9090). These LTA alleles differ only at the commonly studied SNP þ 724 C/A (Thr26Asn). These observations are quite significant when one considers how often this SNP has been linked to other SNPs in both LTA and TNF, to HLA and to expression levels. Thus, linkage should not automatically be assumed.
This study was undertaken to begin to explore the extent of polymorphism in TNF and LTA promoters. It was shown that polymorphism in the promoter regions of TNF and LTA is quite complex. Multiple TNF and LTA promoter alleles were identified and associations were assessed. The data reported here hopefully may provide a resolution to the often ambiguous and contradictory results of studies investigating the associations among SNPs, expression levels, HLA and disease. Studies are currently underway to examine the expression level phenotype of each of the TNF and LTA alleles.
Materials and methods
Cells and sequence-based typing Cells were chosen from IHWS reference cell lines, families and unrelated individuals to include various HLA types and races/ethnicities. In total, 69 samples were characterized for TNF and LTA. 'Alleles' of the TNF promoter and LTA promoter were determined by family segregation analysis and by sequencing (see below) of cloned DNA or homozygous cell lines. Allele level HLA sequence-based typing was performed on the family samples and the unrelated individuals as follows: (1) HLA-DRB1 typing using the HLA-DRB BigDye Terminator Sequence-Based Typing Kit (PE Applied Biosystems, Foster City, CA, USA) as per the manufacturer's protocol, (2) HLA-A and HLA-B typing was performed as previously described at http:/ /www.ihwg.org/components/sbtover.htm and (3) HLA-C genomic DNA amplification was performed as previously described 71 and sequencing was performed as described below. Haplotypes were deduced from MHC homozygous cell lines and from family segregation analysis. The total number of unique TNF/LTA-HLA haplotypes was determined from the samples for which complete haplotypes could be resolved. The number of haplotypes that carry each allele of TNF and of LTA was determined from all samples. Homozygous cell lines were counted as two haplotypes with the exception of consanguineous cell lines 72 whose haplotypes were considered identical by descent and counted only once.
Genomic DNA extraction Genomic DNA was extracted with the DNA Isolation Kit (Pel-Freez; Brown Deer, WI, USA) as per the manufacturer's protocol. Genomic DNA was resuspended in H 2 O (200-500 ml) and stored at À201C. DNA concentration was determined by absorbance at 260 nm.
Amplification of TNF and LTA promoter regions TNF and LTA were amplified from genomic DNA (500 ng) by polymerase chain reaction (PCR) with the primers (20 pm each) TNF5-1 (gatggactcaccaggtgag) and TNF3-1 (ggtgtcctttccaggggag) and with the primers (20 pm each) LTA5-4.2. (ctgacctatctcatctgatagtagg) and LTA3-2 (aggtggatgtttaccaatgag), respectively. Reactions (100 ml) were performed in a Gene Amp 9600 (PerkinElmer, Norwalk, CT, USA) and included Platinum TaqHi Fi (2.5 U) (Invitrogen, Carlsbad, CA, USA), MgSO 4 (2 mM), dNTP mixture (0.2 mM each) and 10 Â buffer (1 Â ). For amplification of the B1.2 kb TNF fragment, the reaction was denatured (10 min, 951C) for one cycle and amplified (30 s, 951C; 30 s, 601C; 1.5 min, 681C) for 35 cycles which was followed by a final extension step (5 min, 681C) for one cycle. Amplification of the B3.2 kb LTA fragment was performed under the following conditions: denaturation (10 min, 951C) for one cycle, amplification (45 s, 951C; 45 s, 581C; 3.5 min, 681C) for 35 cycles and final extension (5 min, 681C) for one cycle. Amplification products were confirmed by agarose gel electrophoresis with DNA size standards. Amplified DNA was purified using the Wizard PCR Preps DNA Purification System (Promega, Madison, WI, USA) as per the manufacturer's protocol with the exception that the DNA was eluted from the column with 70 ml H 2 O.
Sequencing
Purified PCR products (400 ng) were sequenced with the Big Dye Terminator sequencing kit (PE Applied Biosystems, Foster City, CA, USA) in a series of reactions (10 ml) containing primer (5 pm) and Ready Reaction Mix (4 ml). Reactions were purified by ethanol precipitation. Briefly, each reaction was combined with a mixture (25 ml) of ethanol (70%) and sodium acetate pH 4.6 (1 M) and centrifuged (3000 r.p.m., 30 min). Pellets were washed with 70% ethanol (50 ml) and centrifuged (3000 r.p.m., 5 min). Dry pellets were stored at À201C. Pellets were resuspended in 2 ml of a mixture of deionized formamide (100 ml) plus gel loading dye (20 ml), heated (951C, 2 min) and placed directly on ice prior to loading (0.5-1.0 ml). The remaining sample was stored at À201C. Reactions were run on an ABI377 automated DNA sequencer (PE Applied Biosystems, Foster City, CA, USA) according to the manufacturer's protocol. Data were analyzed with Sequencher 4.1 software (Gene Codes Corporation, Ann Arbor, MI, USA). Sequences were reported only when confirmed from data obtained on amplified DNA from at least two separate PCR amplifications.
Cloning TNF and LTA 'alleles' were confirmed by cloning and sequencing of multiple clones. Amplified products were cloned into the TA cloning vector (Invitrogen, Carlsbad, CA, USA) as per the manufacturer's protocol. Individual clones were harvested in 50 ml of water and lysed (951C, 5 min). Lysed clones were centrifuged and lysates were stored at 41C. Lysate (10 ml) was amplified by PCR with corresponding primer sets (as described above). Amplified products were sequenced as described above.
Phylogenetic analysis and percentage difference
Phylogenetic trees were constructed with PAUP software (version 4.0.0b10; Sinauer Associates, http:/ /www.sinauer.com) using the neighbor-joining method with a Kimura two-parameter correction. The branch length of the unrooted phylograms shows relative genetic distance between alleles. Percentage difference analysis was performed using PercentDif, a program developed inhouse using Perl, version 5.6.1. This program was based on an analysis by Rajalingam et al. 73 Sequences were aligned in Sequencher 4.1 software (as above) and imported into the PercentDif program. The percentage difference is calculated between each member of the alignment as compared to a designated reference sequence. The program calculates percentage difference between two sequences by comparing the number of gaps and mismatches over the length that the two sequences overlap. Sequences LTAp*012 and AF037255 have a 145 bp insertion that was not taken into account in either analysis so as to better ascertain its relatedness to the remaining 'alleles'.
